Literature DB >> 34553495

Applications of the versatile CRISPR-Cas13 RNA targeting system.

Martyna Kordyś1, Raneet Sen, Zbigniew Warkocki.   

Abstract

CRISPR-Cas are adaptable natural prokaryotic defense systems that act against invading viruses and plasmids. Among the six currently known major CRISPR-Cas types, the type VI CRISPR-Cas13 is the only one known to exclusively bind and cleave foreign RNA. Within the last couple of years, this system has been adapted to serve numerous, and sometimes not obvious, applications, including some that might be developed as effective molecular therapies. Indeed, Cas13 has been adapted to kill antibiotic-resistant bacteria. In a cell-free environment, Cas13 has been used in the development of highly specific, sensitive, multiplexing-capable, and field-adaptable detection tools. Importantly, Cas13 can be reprogrammed and applied to eukaryotes to either combat pathogenic RNA viruses or in the regulation of gene expression, facilitating the knockdown of mRNA, circular RNA, and noncoding RNA. Furthermore, Cas13 has been harnessed for in vivo RNA modifications including programmable regulation of alternative splicing, A-to-I and C to U editing, and m6A modifications. Finally, approaches allowing for the detection and characterization of RNA-interacting proteins have also been demonstrated. Here, we provide a comprehensive overview of the applications utilizing CRISPR-Cas13 that illustrate its versatility. We also discuss the most important limitations of the CRISPR-Cas13-based technologies, and controversies regarding them. This article is categorized under: RNA Methods > RNA Analyses in Cells RNA Processing > RNA Editing and Modification RNA Interactions with Proteins and Other Molecules > Protein-RNA Interactions: Functional Implications.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CRISPR-Cas13; RNA editing; RNA methods; bactericidal agents; gene knockdown

Mesh:

Substances:

Year:  2021        PMID: 34553495     DOI: 10.1002/wrna.1694

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  4 in total

1.  RNA targeting using CasRx can prevent aminoglycoside-induced hearing loss.

Authors:  Xavier Bofill-De Ros
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-19       Impact factor: 10.183

2.  CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells.

Authors:  Yuxi Ai; Dongming Liang; Jeremy E Wilusz
Journal:  Nucleic Acids Res       Date:  2022-06-24       Impact factor: 19.160

Review 3.  Applications of CRISPR/Cas13-Based RNA Editing in Plants.

Authors:  Naga Rajitha Kavuri; Manikandan Ramasamy; Yiping Qi; Kranthi Mandadi
Journal:  Cells       Date:  2022-08-27       Impact factor: 7.666

Review 4.  Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.

Authors:  Li Liu; De-Sheng Pei
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.